NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-28 16:27இன்று 33 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Veerhealth Care Targets ₹100 Cr FY27 Turnover with ₹5-6 Cr PAT in Investor Call
Veerhealth Care released the transcript of its October 24, 2026 investor meeting detailing aggressive operational growth. The management stated it aims to close FY27 with approximately ₹100 crore in turnover and ₹5-6 crore in PAT, compared to TTM revenue of ₹53 crore. In Q1 FY27, revenue reached ₹25 crore with ₹1.25 crore PAT, driven 70% by contract manufacturing, 20% by exports, and 10% by own brands. The company is operating at 65-70% capacity at its Vapi facility, which will rise toward 90% post-expansion.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the verbatim transcript of the investor conference call held on October 24, 2026, outlining full-year targets and CDMO operational performance.
ஏன் இது முக்கியம்Management is guiding for an almost doubling of annual scale (₹100 crore target vs ₹53 crore TTM revenue), supported by US FDA certification and tie-ups with leading Indian FMCG players.
FY26-27 Revenue Target: approximately 100 croresFY26-27 PAT Target: around 5 to 6 CRFY27 Target vs TTM Revenue: ~188.7%Current Capacity Utilization: 65 to 70 percentFacility Footprint Expansion: 60,000 to 90,000 square feet
📅 குறுகிய காலம்Market sentiment may view the ₹100 crore guidance favorably, though confirmation depends on subsequent quarterly reporting.
📈 நீண்ட காலம்If the company scales CDMO volumes to achieve 90% utilization and enters hospitality supply chains, operational operating leverage could expand profitability beyond historic single-digit OPM levels.
⚠ அபாய எச்சரிக்கைகள்
Promoter holding is relatively low at 31.5%
High customer concentration in CDMO segment
Working capital stretch indicated by rising receivables and payables
👀 கவனிக்க வேண்டியவை
Track the upcoming Q2 FY27 financial results to confirm if quarterly run-rate sustains near ₹25 crore to remain on course for the ₹100 crore annual revenue guidance.
Veerhealth Care Bags Rs 4.55 Cr Skincare Supply Order from Domestic FMCG Major
Veerhealth Care Ltd has secured an order worth Rs 454.68 Lakhs (approx. Rs 4.55 crore) for the supply of face care products from an unnamed leading domestic FMCG company. The order comes with a short execution timeline of 45 days. Relative to the company's TTM revenue of Rs 53 crore, this single order represents approximately 8.6%, offering immediate quarterly revenue visibility. The contract is non-related party and awarded on an arm's length basis.
உச்சம் நம்பிக்கை
என்ன மாறியதுVeerhealth Care secured a Rs 454.68 Lakh contract for face care products from a domestic FMCG player.
ஏன் இது முக்கியம்The order value constitutes ~8.6% of TTM revenue (Rs 53 Cr) and provides strong short-term top-line support due to its rapid 45-day execution requirement.
Order value: Rs. 454.68/- LakhsExecution timeframe: 45 DaysOrder vs TTM revenue: ~8.6%
📅 குறுகிய காலம்Positive for Q3 FY27 revenue given that execution is required within 45 days.
📈 நீண்ட காலம்Demonstrates contract manufacturing traction with leading FMCG players, but long-term impact depends on repeat order frequency.
⚠ அபாய எச்சரிக்கைகள்
Client name withheld due to confidentiality terms
Tight 45-day execution deadline
👀 கவனிக்க வேண்டியவை
Monitor whether the delivery is completed within the stated 45-day window and reflected in the upcoming Q3 FY27 financial results.
Veerhealth Care Q1 Revenue Surges 388% YoY to Rs 25.09 Cr; FY27 Target at Rs 105 Cr
Veerhealth Care reported a 388.13% YoY surge in Q1FY27 total revenue to Rs 25.09 crore, with net profit rising 412.50% YoY to Rs 1.23 crore. The company highlighted major order wins in FY27, including Rs 32.93 crore from a New York-based firm and Rs 18.24 crore from a domestic FMCG firm. Management issued strong guidance targeting Rs 105 crore in total income with Rs 5-6 crore PAT for FY27, and Rs 156 crore total income for FY28. Growth is supported by a newly commenced manufacturing facility and USFDA plant clearance for OTC exports.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported record quarterly revenue of Rs 25.09 crore, commissioned its new manufacturing facility, and set an aggressive FY27 revenue target of Rs 105 crore.
ஏன் இது முக்கியம்The FY27 target of Rs 105 crore is nearly double its TTM revenue (~Rs 53 crore), driven by export expansion following USFDA OTC plant clearance and new production lines.
📅 குறுகிய காலம்Strong operational momentum and sizeable order pipeline are likely to support near-term sentiment.
📈 நீண்ட காலம்Successful scale-up in US and international OTC markets along with backward integration could significantly enhance operational scale over FY27-FY28.
⚠ அபாய எச்சரிக்கைகள்
Execution and delivery risk on large export contracts
Veerhealth Care Q1 PAT Jumps to ₹1.23 Cr; Revenue Up 455% YoY; New CS Appointed
Veerhealth Care reported a massive surge in Q1 FY27 (June 2026) revenue to ₹24.93 Cr, a 455% increase compared to ₹4.49 Cr in the same quarter last year. The company turned profitable with a net profit of ₹1.23 Cr, recovering from a loss of ₹0.35 Cr in the preceding March 2026 quarter. Additionally, the company has received ₹4.87 Cr as part payment for 1 crore warrants issued at ₹20.25 each. The board also appointed Ruchi Shah, daughter of the Chairperson, as the new Company Secretary following the resignation of Ashita Chittora.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company achieved a significant scale-up in quarterly revenue and profitability while transitioning its compliance leadership to a promoter-related individual.
ஏன் இது முக்கியம்The financial performance indicates a potential structural shift in business volume, as Q1 revenue alone is nearly 77% of the entire previous financial year's revenue. The warrant fundraise provides growth capital but introduces dilution risks.
📅 குறுகிய காலம்The stock is likely to react positively to the strong earnings turnaround and massive YoY revenue growth.
📈 நீண்ட காலம்If the company sustains this new quarterly revenue run-rate, it could lead to a significant re-rating, though the high P/E and promoter-related management appointment warrant caution.
⚠ அபாய எச்சரிக்கைகள்
Related-party appointment (CS is daughter of Chairperson)
👀 கவனிக்க வேண்டியவை
Investors should monitor if the sharp revenue spike in Q1 (which represents ~77% of total FY26 revenue) is sustainable or due to a one-off bulk order. Watch for the full conversion of warrants and the resulting equity dilution.
₹24.93 Cr Revenue: Veerhealth Care Reports 455% YoY Growth in Q1 FY27
Veerhealth Care reported a massive surge in Q1 FY27 revenue to ₹24.93 cr, a 455% increase from ₹4.49 cr in the same quarter last year. Net profit rose to ₹1.23 cr compared to ₹0.24 cr YoY, marking a sharp recovery from the ₹0.35 cr loss in the preceding March 2026 quarter. The company also confirmed receiving ₹4.87 cr as part payment for a ₹20.25 cr warrant issue. Additionally, the Board appointed Ruchi Shah, daughter of the Chairperson, as the new Company Secretary following the resignation of the incumbent.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company delivered record quarterly revenue and profit, significantly exceeding its historical quarterly averages and turning around from a loss in the previous quarter.
ஏன் இது முக்கியம்The scale of operations has shifted dramatically; Q1 FY27 revenue alone represents approximately 77% of the entire FY26 annual revenue (₹32.48 cr), suggesting a potential structural change in business volume.
Revenue (Q1 FY27): ₹24.93 கோடிNet Profit (Q1 FY27): ₹1.23 கோடிQ1 Revenue vs FY26 Total Revenue: 76.7%Warrant Issue Total Value: ₹20.25 கோடிWarrant Funds Received to date: ₹4.87 கோடி
📅 குறுகிய காலம்The stock is likely to react positively to the significant top-line and bottom-line growth and the successful turnaround from the previous quarter's loss.
📈 நீண்ட காலம்If the company maintains this new scale of operations, it could lead to a significant re-rating, though the low promoter holding (31.5%) and high P/E remain key monitoring points.
⚠ அபாய எச்சரிக்கைகள்
Related-party appointment (New CS is daughter of Chairperson)
Low promoter holding at 31.5%
Potential equity dilution from 1 crore warrant conversions
👀 கவனிக்க வேண்டியவை
Investors should monitor if this high revenue run-rate is sustainable or driven by one-off bulk orders, and track the conversion of warrants which will lead to equity dilution.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
₹5.27 Cr Repeat Order from Leading FMCG Group; FY27 Revenue Target Set at ₹105 Cr
Veerhealth Care has secured a repeat monthly order worth ₹5.27 Crores from a prominent 125-year-old Indian FMCG group for face care products. This single order represents approximately 16.5% of the company's TTM revenue and is scheduled for execution within 45 days. Additionally, the company has entered the Sudan market with a ₹15.74 lakh sample order for Gripe Water. Management has issued aggressive guidance, targeting ₹105 Crores in revenue for FY27, which would be a 223% increase over FY26 revenue of ₹32.48 Crores.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company secured a significant repeat order from a major domestic client and provided high-growth financial guidance for the next two fiscal years.
ஏன் இது முக்கியம்For a micro-cap company with ₹32 Cr in TTM revenue, a ₹5.27 Cr monthly repeat order is highly material, validating its manufacturing capabilities for large FMCG players and supporting a potential multi-year growth trajectory.
Order Value: ₹5.27 கோடிOrder vs TTM Revenue: ~16.5%FY27 Revenue Guidance: ₹105 கோடிFY26 Revenue: ₹32.48 கோடிExecution Timeline: 45 நாட்கள்
📅 குறுகிய காலம்The stock may see positive momentum due to the materiality of the order and the aggressive forward-looking guidance provided by management.
📈 நீண்ட காலம்If the company achieves its FY27 and FY28 targets (₹105 Cr and ₹156 Cr respectively), it would represent a significant structural scale-up from its current base, though execution risk remains high given the current low margins.
⚠ அபாய எச்சரிக்கைகள்
Aggressive growth targets (3x revenue in one year)
👀 கவனிக்க வேண்டியவை
Investors should monitor the quarterly revenue run-rate to see if it aligns with the ambitious ₹105 Cr annual target. Key execution milestones include the successful delivery of the current ₹5.27 Cr order and the conversion of 'advanced talks' with the hotel amenities supplier into firm contracts.
₹5.27 Cr Skincare Order from Large FMCG Company to be Executed in 45 Days
Veerhealth Care has secured a domestic order worth ₹526.84 Lakhs (₹5.27 Cr) for the supply of face care products to a major Indian FMCG company. This single order is highly material, representing approximately 16.5% of the company's total FY26 revenue of ₹32.48 Cr. The contract requires rapid execution within a 45-day window, which is expected to significantly impact the immediate quarterly turnover. While the client's identity is withheld due to confidentiality, the scale of the win is substantial for a micro-cap company with an ₹84 Cr market valuation.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from smaller-scale operations to securing a high-value, short-cycle contract from a major domestic FMCG player.
ஏன் இது முக்கியம்For a micro-cap company, this order provides significant revenue visibility and demonstrates the capability to meet the standards of large-scale FMCG clients, potentially leading to repeat business.
Order Value: ₹526.84 லட்சம்Execution Period: 45 DaysOrder vs TTM Revenue: ~16.5%TTM வருவாய்: ₹32 கோடிசந்தை மதிப்பு: ₹84 கோடி
📅 குறுகிய காலம்The stock may see positive momentum as the market reacts to a material order win that will be fully reflected in the financials within the next two months.
📈 நீண்ட காலம்If this leads to a sustained relationship with large FMCG clients, it could structurally improve the company's scale and capacity utilization over the coming years.
⚠ அபாய எச்சரிக்கைகள்
Tight execution window of 45 days
Client concentration risk as the name is not disclosed
👀 கவனிக்க வேண்டியவை
Investors should monitor the September 2026 quarterly results to verify the successful execution of this order and its impact on operating margins, which stood at 7.6% in FY26.
Rs 76.40 Lakh Sample Order from Leading FMCG Group for Skincare Products
Veerhealth Care has secured a sample order worth Rs 76.40 lakhs from a prominent 125-year-old Indian FMCG group for skincare products. While the order is small at approximately 2.4% of TTM revenue, it is strategically significant as it involves a new MRP structure for brand promotion and market expansion. The company has also issued aggressive forward guidance, targeting a revenue of Rs 105 crore in FY27, which is more than 3x its current TTM revenue of Rs 32 crore. Execution of this specific order is expected within 45 days.
உச்சம் நம்பிக்கை
என்ன மாறியதுVeerhealth Care has initiated a supply relationship with a major FMCG group and provided specific multi-year financial targets for the first time.
ஏன் இது முக்கியம்The association with a large FMCG group validates the company's manufacturing quality; however, the aggressive guidance (3x revenue growth by FY27) sets a high bar for execution that will determine future valuation.
📅 குறுகிய காலம்The news is likely to be viewed positively by the market due to the pedigree of the client and the high growth projections, potentially supporting the recent momentum in the stock.
📈 நீண்ட காலம்The long-term outlook depends entirely on the company's ability to scale from Rs 32 crore to Rs 105 crore in revenue by FY27 while improving its currently low OPM of 7.6%.
⚠ அபாய எச்சரிக்கைகள்
High P/E ratio of 152.2 indicates significant growth is already priced in
Relatively low promoter holding at 31.5%
Execution risk in meeting aggressive 3x revenue growth targets
👀 கவனிக்க வேண்டியவை
Investors should monitor the conversion of this sample order into larger recurring contracts and track quarterly revenue growth against the company's ambitious FY27 target of Rs 105 crore.
₹1.11 Cr Repeat Order; Co. Targets ₹105 Cr Revenue in FY27 via ₹20.25 Cr Fundraise
Veerhealth Care has received a repeat order worth ₹1.11 crores for hair and oral care products from a major Indian pharmacy and hospital network, with execution slated within 45 days. The company has issued aggressive financial guidance, targeting a total income of ~₹105 crores in FY27 and ~₹156 crores in FY28. To fund this growth, the company is raising capital through the allotment of 1,00,00,000 convertible warrants at ₹20.25 each. Promoters are demonstrating confidence by subscribing to 45.37% of the total warrant issue.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company secured a repeat contract from a major client and formalized a significant capital raising plan to fund future expansion and meet high-growth revenue targets.
ஏன் இது முக்கியம்The repeat order validates the company's product quality with large-scale institutional buyers, while the ₹20.25 crore fundraise provides the necessary liquidity for capacity expansion to reach its ₹100cr+ revenue goals.
Repeat Order Value: ₹1.11 கோடிFY27 Revenue Guidance: ~₹105 croresWarrant Issue Price: ₹20.25Total Warrants Allotted: 1,00,00,000Execution Timeline: 45 நாட்கள்Book Value per share (FY26): ₹11.46
📅 குறுகிய காலம்The stock may see positive momentum driven by the order win and the clear, high-growth financial guidance provided for the next two fiscal years.
📈 நீண்ட காலம்The structural outlook depends on the company's ability to execute its expansion plan using warrant proceeds and achieving the projected 5-10x growth in revenue by FY28.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in meeting high-growth revenue targets
Equity dilution from the conversion of 1 crore warrants
Reliance on forward-looking management projections
👀 கவனிக்க வேண்டியவை
Monitor the company's ability to scale operations to meet the ambitious ₹105 crore revenue target for FY27 and track the successful conversion of warrants into equity.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
